MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP - Toronto Stock Exchange - CA58410Q2036 - Common Stock - Currency: CAD
Overall MDP gets a fundamental rating of 4 out of 10. We evaluated MDP against 35 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of MDP get a neutral evaluation. Nothing too spectacular is happening here. MDP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MDP had negative earnings in the past year.
In the past year MDP had a positive cash flow from operations.
MDP had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 2.44%, MDP belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
The Return On Equity of MDP (10.76%) is better than 87.88% of its industry peers.
MDP's Return On Invested Capital of 13.60% is amongst the best of the industry. MDP outperforms 93.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.44% | ||
| ROE | 10.76% | ||
| ROIC | 13.6% |
ROA(3y)-0.48%
ROA(5y)-5.11%
ROE(3y)-3.82%
ROE(5y)-38.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDP has a Profit Margin of 3.25%. This is amongst the best in the industry. MDP outperforms 84.85% of its industry peers.
The Operating Margin of MDP (13.73%) is better than 87.88% of its industry peers.
MDP has a better Gross Margin (52.45%) than 75.76% of its industry peers.
MDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 3.25% | ||
| GM | 52.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-2.29%
2. Health
2.1 Basic Checks
MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, MDP has more shares outstanding
Compared to 5 years ago, MDP has more shares outstanding
The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
MDP has an Altman-Z score of 0.85. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.85, MDP is in the better half of the industry, outperforming 75.76% of the companies in the same industry.
The Debt to FCF ratio of MDP is 1.95, which is an excellent value as it means it would take MDP, only 1.95 years of fcf income to pay off all of its debts.
MDP has a Debt to FCF ratio of 1.95. This is amongst the best in the industry. MDP outperforms 90.91% of its industry peers.
A Debt/Equity ratio of 0.67 indicates that MDP is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.67, MDP is doing worse than 66.67% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for MDP, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.67 | ||
| Debt/FCF | 1.95 | ||
| Altman-Z | 0.85 |
ROIC/WACC1.54
WACC8.82%
2.3 Liquidity
MDP has a Current Ratio of 1.01. This is a normal value and indicates that MDP is financially healthy and should not expect problems in meeting its short term obligations.
MDP has a Current ratio of 1.01. This is in the lower half of the industry: MDP underperforms 78.79% of its industry peers.
A Quick Ratio of 0.49 indicates that MDP may have some problems paying its short term obligations.
MDP has a Quick ratio of 0.49. This is in the lower half of the industry: MDP underperforms 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.49 |
3. Growth
3.1 Past
MDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.00%, which is quite impressive.
The Revenue has decreased by -5.34% in the past year.
Measured over the past years, MDP shows a very strong growth in Revenue. The Revenue has been growing by 27.27% on average per year.
EPS 1Y (TTM)80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%234.56%
Revenue 1Y (TTM)-5.34%
Revenue growth 3Y12.38%
Revenue growth 5Y27.27%
Sales Q2Q%18.96%
3.2 Future
The Earnings Per Share is expected to grow by 131.62% on average over the next years. This is a very strong growth
MDP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.75% yearly.
EPS Next Y410.57%
EPS Next 2Y-272.66%
EPS Next 3Y259.44%
EPS Next 5Y131.62%
Revenue Next Year-4.93%
Revenue Next 2Y-6.29%
Revenue Next 3Y2.86%
Revenue Next 5Y3.75%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MDP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
96.97% of the companies in the same industry are more expensive than MDP, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 96.97% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.17 | ||
| EV/EBITDA | 4.54 |
4.3 Compensation for Growth
MDP's earnings are expected to grow with 259.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-272.66%
EPS Next 3Y259.44%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (2/21/2025, 7:00:00 PM)
2.87
-0.12 (-4.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.93%
Inst Owner ChangeN/A
Ins Owners7.34%
Ins Owner ChangeN/A
Market Cap92.27M
Analysts81.82
Price Target6.27 (118.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.8%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)9.98%
Revenue beat(4)2
Avg Revenue beat(4)1.5%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)9.98%
Revenue beat(8)4
Avg Revenue beat(8)-0.58%
Revenue beat(12)7
Avg Revenue beat(12)1.65%
Revenue beat(16)8
Avg Revenue beat(16)-5.93%
PT rev (1m)34.11%
PT rev (3m)61.49%
EPS NQ rev (1m)-72.52%
EPS NQ rev (3m)-130%
EPS NY rev (1m)-23.12%
EPS NY rev (3m)-67.29%
Revenue NQ rev (1m)3.14%
Revenue NQ rev (3m)-13.54%
Revenue NY rev (1m)2.94%
Revenue NY rev (3m)3.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.59 | ||
| P/FCF | 3.17 | ||
| P/OCF | 2.78 | ||
| P/B | 1.96 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.54 |
EPS(TTM)-0.01
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)0.9
FCFY31.5%
OCF(TTM)1.03
OCFY35.95%
SpS4.84
BVpS1.46
TBVpS-1.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.44% | ||
| ROE | 10.76% | ||
| ROCE | 18.88% | ||
| ROIC | 13.6% | ||
| ROICexc | 15.21% | ||
| ROICexgc | 569.19% | ||
| OM | 13.73% | ||
| PM (TTM) | 3.25% | ||
| GM | 52.45% | ||
| FCFM | 18.69% |
ROA(3y)-0.48%
ROA(5y)-5.11%
ROE(3y)-3.82%
ROE(5y)-38.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-2.29%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.67 | ||
| Debt/FCF | 1.95 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 46.7% | ||
| Cap/Sales | 2.64% | ||
| Interest Coverage | 3.16 | ||
| Cash Conversion | 110.07% | ||
| Profit Quality | 574.79% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.49 | ||
| Altman-Z | 0.85 |
F-Score5
WACC8.82%
ROIC/WACC1.54
Cap/Depr(3y)45.36%
Cap/Depr(5y)67.78%
Cap/Sales(3y)3.54%
Cap/Sales(5y)5.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%234.56%
EPS Next Y410.57%
EPS Next 2Y-272.66%
EPS Next 3Y259.44%
EPS Next 5Y131.62%
Revenue 1Y (TTM)-5.34%
Revenue growth 3Y12.38%
Revenue growth 5Y27.27%
Sales Q2Q%18.96%
Revenue Next Year-4.93%
Revenue Next 2Y-6.29%
Revenue Next 3Y2.86%
Revenue Next 5Y3.75%
EBIT growth 1Y17.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.85%
EBIT Next 3Y20.96%
EBIT Next 5Y30.02%
FCF growth 1Y706.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1632.13%
OCF growth 3Y54.85%
OCF growth 5YN/A